The History of Vaccination Against Cytomegalovirus

Overview

Journal Med Microbiol Immunol

Specialty Allergy & Immunology

Date 2015 Mar 21

PMID 25791890

Citations 39

Authors

Stanley Plotkin

Affiliations

Soon will be listed here.

Abstract

Cytomegalovirus vaccine development started in the 1970s with attenuated strains. In the 1980s, one of the strains was shown to be safe and effective in renal transplant patients. Then, attention switched to glycoprotein gB, which was shown to give moderate but transient protection against acquisition of the virus by women. The identification of the pp65 tegument protein as the principal target of cellular immune responses resulted in new approaches, particularly DNA, plasmids to protect hematogenous stem cell recipients. The subsequent discovery of the pentameric protein complex that generates most neutralizing antibodies led to efforts to incorporate that complex into vaccines. At this point, there are many candidate CMV vaccines, including live recombinants, replication-defective virus, DNA plasmids, soluble pentameric proteins, peptides, virus-like particles and vectored envelope proteins.

Citing Articles

Immune surveillance of cytomegalovirus in tissues.

Mihalic A, Zeleznjak J, Lisnic B, Jonjic S, Juranic Lisnic V, Brizic I Cell Mol Immunol. 2024; 21(9):959-981.

PMID: 39134803 PMC: 11364667. DOI: 10.1038/s41423-024-01186-2.

Late-rising CD4 T cells resolve mouse cytomegalovirus persistent replication in the salivary gland.

Brunel S, Picarda G, Gupta A, Ghosh R, McDonald B, El Morabiti R PLoS Pathog. 2024; 20(1):e1011852.

PMID: 38236791 PMC: 10796040. DOI: 10.1371/journal.ppat.1011852.

M-CSF directs myeloid and NK cell differentiation to protect from CMV after hematopoietic cell transplantation.

Kandalla P, Subburayalu J, Cocita C, de Laval B, Tomasello E, Iacono J EMBO Mol Med. 2023; 15(11):e17694.

PMID: 37635627 PMC: 10630876. DOI: 10.15252/emmm.202317694.

Maternal vaccination: a review of current evidence and recommendations.

Etti M, Calvert A, Galiza E, Lim S, Khalil A, Le Doare K Am J Obstet Gynecol. 2021; 226(4):459-474.

PMID: 34774821 PMC: 8582099. DOI: 10.1016/j.ajog.2021.10.041.

Localization of Viral Epitope-Specific CD8 T Cells during Cytomegalovirus Latency in the Lungs and Recruitment to Lung Parenchyma by Airway Challenge Infection.

Blaum F, Lukas D, Reddehase M, Lemmermann N Life (Basel). 2021; 11(9).

PMID: 34575067 PMC: 8467276. DOI: 10.3390/life11090918.

References

Fleisher G, Starr S, Friedman H, Plotkin S . Vaccination of pediatric nurses with live attenuated cytomegalovirus. Am J Dis Child. 1982; 136(4):294-6. DOI: 10.1001/archpedi.1982.03970400012003. View

Wen Y, Monroe J, Linton C, Archer J, Beard C, Barnett S . Human cytomegalovirus gH/gL/UL128/UL130/UL131A complex elicits potently neutralizing antibodies in mice. Vaccine. 2014; 32(30):3796-804. DOI: 10.1016/j.vaccine.2014.05.004. View

Carney W, Hirsch M, Iacoviello V, Starr S, Fleisher G, Plotkin S . T-lymphocyte subsets and proliferative responses following immunization with cytomegalovirus vaccine. J Infect Dis. 1983; 147(5):958. DOI: 10.1093/infdis/147.5.958. View

Plotkin S, HUYGELEN C . Cytomegalovirus vaccine prepared in WI-38. Dev Biol Stand. 1976; 37:301-5. View

Gonczol E, Hudecz F, Ianacone J, Dietzschold B, STARR S, Plotkin S . Immune responses to isolated human cytomegalovirus envelope proteins. J Virol. 1986; 58(2):661-4. PMC: 252959. DOI: 10.1128/JVI.58.2.661-664.1986. View

Plotkin S, Farquhar J, Horberger E . Clinical trials of immunization with the Towne 125 strain of human cytomegalovirus. J Infect Dis. 1976; 134(5):470-5. DOI: 10.1093/infdis/134.5.470. View

Osawa R, Singh N . Cytomegalovirus infection in critically ill patients: a systematic review. Crit Care. 2009; 13(3):R68. PMC: 2717427. DOI: 10.1186/cc7875. View

Genini E, Percivalle E, Sarasini A, Revello M, Baldanti F, Gerna G . Serum antibody response to the gH/gL/pUL128-131 five-protein complex of human cytomegalovirus (HCMV) in primary and reactivated HCMV infections. J Clin Virol. 2011; 52(2):113-8. DOI: 10.1016/j.jcv.2011.06.018. View

Malouli D, Hansen S, Nakayasu E, Marshall E, Hughes C, Ventura A . Cytomegalovirus pp65 limits dissemination but is dispensable for persistence. J Clin Invest. 2014; 124(5):1928-44. PMC: 4002596. DOI: 10.1172/JCI67420. View

10.

Friedman A, Furukawa T, Plotkin S . Detection of antibody to cytomegalovirus early antigen in vaccinated, normal volunteers and renal transplant candidates. J Infect Dis. 1982; 146(2):255-9. DOI: 10.1093/infdis/146.2.255. View

11.

Lanzieri T, Bialek S, Ortega-Sanchez I, Gambhir M . Modeling the potential impact of vaccination on the epidemiology of congenital cytomegalovirus infection. Vaccine. 2014; 32(30):3780-6. PMC: 4843116. DOI: 10.1016/j.vaccine.2014.05.014. View

12.

Starr S, Glazer J, Friedman H, FARQUHAR J, Plotkin S . Specific cellular and humoral immunity after immunization with live Towne strain cytomegalovirus vaccine. J Infect Dis. 1981; 143(4):585-9. DOI: 10.1093/infdis/143.4.585. View

13.

NEFF B, WEIBEL R, BUYNAK E, McLEAN A, HILLEMAN M . Clinical and laboratory studies of live cytomegalovirus vaccine Ad-169. Proc Soc Exp Biol Med. 1979; 160(1):32-7. DOI: 10.3181/00379727-160-40382. View

14.

Heineman T, Schleiss M, Bernstein D, Spaete R, Yan L, Duke G . A phase 1 study of 4 live, recombinant human cytomegalovirus Towne/Toledo chimeric vaccines. J Infect Dis. 2006; 193(10):1350-60. DOI: 10.1086/503365. View

15.

Gyulai Z, Endresz V, Burian K, Pincus S, Toldy J, Cox W . Cytotoxic T lymphocyte (CTL) responses to human cytomegalovirus pp65, IE1-Exon4, gB, pp150, and pp28 in healthy individuals: reevaluation of prevalence of IE1-specific CTLs. J Infect Dis. 2000; 181(5):1537-46. DOI: 10.1086/315445. View

16.

Plotkin S, WEIBEL R, Alpert G, Starr S, Friedman H, Preblud S . Resistance of seropositive volunteers to subcutaneous challenge with low-passage human cytomegalovirus. J Infect Dis. 1985; 151(4):737-9. DOI: 10.1093/infdis/151.4.737. View

17.

Frey S, Harrison C, Pass R, Yang E, Boken D, Sekulovich R . Effects of antigen dose and immunization regimens on antibody responses to a cytomegalovirus glycoprotein B subunit vaccine. J Infect Dis. 1999; 180(5):1700-3. DOI: 10.1086/315060. View

18.

Jacobson M, Sinclair E, Bredt B, Agrillo L, Black D, Epling C . Antigen-specific T cell responses induced by Towne cytomegalovirus (CMV) vaccine in CMV-seronegative vaccine recipients. J Clin Virol. 2006; 35(3):332-7. DOI: 10.1016/j.jcv.2005.09.019. View

19.

Barkai G, Ari-Even Roth D, Barzilai A, Tepperberg-Oikawa M, Mendelson E, Hildesheimer M . Universal neonatal cytomegalovirus screening using saliva - report of clinical experience. J Clin Virol. 2014; 60(4):361-6. DOI: 10.1016/j.jcv.2014.04.024. View

20.

La Rosa C, Longmate J, Lacey S, Kaltcheva T, Sharan R, Marsano D . Clinical evaluation of safety and immunogenicity of PADRE-cytomegalovirus (CMV) and tetanus-CMV fusion peptide vaccines with or without PF03512676 adjuvant. J Infect Dis. 2012; 205(8):1294-304. PMC: 3308906. DOI: 10.1093/infdis/jis107. View